Accessibility StatementSkip Navigation FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revelloâ"¢ Vascular Covered Stent in patients with peripheral arterial disease (PAD). Continue Reading BD Achieves Milestone in AGILITY Study of Revel ...

文章核心观点 - 公司在第三季度保持增长势头，通过人工智能创新和长期合作伙伴关系推动业绩，在不确定的宏观环境下仍按计划推进 [2] - 公司重申对2025年全年业绩指引的信心，并预计利润率将处于指引范围的高端 [8][11] 集团及部门业绩 - 可比订单量增长8%，集团销售额达43亿欧元，可比销售额增长3.3%，所有业务部门均实现增长 [4][8] - 调整后息税摊销前利润率扩大50个基点至12.3%，主要受销售额增长、有利的产品组合效应和生产力提升推动，抵消了关税增加的影响 [4][8] - 自由现金流增加至1.72亿欧元，营运现金流为3.27亿欧元 [4][8] - 诊断与治疗业务可比销售额增长1.3%，调整后息税摊销前利润率为11.8%，下降80个基点 [5] - 互联关护业务可比销售额增长5.1%，调整后息税摊销前利润率改善410个基点至11.4% [5] - 个人健康业务可比销售额增长10.9%，调整后息税摊销前利润率提升60个基点至17.1% [6] 创新亮点 - 在美国推出Lumea IPL（强脉冲光脱毛仪），该品牌为全球第一，上市初期即获得强劲的消费者关注 [9] - 发布放射治疗突破性产品，包括先进的Rembra RT和Areta RT CT扫描仪，并在北美推出无氦BlueSeal RT MR [9] - 推出新一代心血管超声系统Transcend Plus、EPIQ CVx和Affiniti CVx，包含26个获FDA批准的心血管超声AI应用，为行业最多 [9] 生产力与成本管理 - 严格的成本管理和稳健的生产力计划在本季度带来2.22亿欧元的节约 [10] - 公司将执行为期三年、总额25亿欧元的生产力计划，其中2025年计划实现8亿欧元的节约 [10] 合作伙伴关系与可持续发展 - 与美国加州领先医疗系统（如橙郡Hoag医院和圣地亚哥Rady儿童医院）签署长期企业监护即服务合作伙伴关系 [14] - 公司到2045年实现净零排放的科学基础目标已获科学碳目标倡议正式验证 [14] - 与印度尼西亚卫生部的里程碑式协议进入实施阶段，首套Azurion系统正在东爪哇安装 [3]

November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA margin increased by 50 basis points to 12.3% of salesOperating cash flow of EUR 327 million, with a free cash flow of EUR 172 millionPhilips reiterates full-year 2025 outlook, with margin now expected at the upper end of the range Roy Jakobs, CEO of Royal Philips:“In this quarter we maintained our ...

Accessibility StatementSkip Navigation ALAMEDA, Calif., Nov. 3, 2025 /PRNewswire/ --Â Penumbra, Inc. (NYSE: PEN) announced additional results of the ground- breaking STORM-PE randomized controlled trial (RCT), which found that the use of computer assisted vacuum thrombectomy (CAVTâ"¢) with anticoagulation achieved significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to anticoagulation alone in patients with acute intermediate-high ...

Accessibility StatementSkip Navigation more press release views with Request a Demo Also from this source Cardinal Health launches a new all-in-one solution for deep vein thrombosis and pulmonary embolism prevention Cardinal Health has announced the international launch of its Kendall SCD SmartFlowâ"¢ Compression System, the next generation of the Kendallâ"¢... Adds the country's leading urology MSO with over 750 providers to Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance an ...

Accessibility StatementSkip Navigation The objective of the independent retrospective observational study was to evaluate the effectiveness of combining SBRT with cryoablation for treating stage I NSCLC tumors 2 cm, given the limitations of local control and survival rates with SBRT monotherapy. 64 patients with tumors of mean diameter of 2.7 ± 0.5 cm and a range of 2.0–4.0 cm were treated with SBRT, followed by cryoablation. The median follow-up duration was 74 months, with a range of 3-111 months. Results ...

FRANKLIN LAKES, N.J., Nov. 3, 2025 /PRNewswire/ --Â BD (Becton, Dickinson and Company) (NYSE: BDX)Â a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformité Européenne (CE) marking in the European Union for its Enteric Bacterial Panel* (EBP) and Enteric Bacterial Panel plus* (EBP plus) for the BD CORâ"¢ System. Continue Reading BD Receives FDA 510(k) Clearance and CE-IVDR Certification for High-Throughput Enteric Bac ...

Accessibility StatementSkip Navigation BAD HOMBURG, Germany, Oct. 30, 2025 /PRNewswire/ -- Fresenius Medical Care AG (FME), the world's leading provider of products and services for people with kidney diseases, will present new research showing how hemodiafiltration (HDF) is associated with improved outcomes for kidney patients and how innovations in artificial intelligence (AI) can support clinicians in daily care at the American Society of Nephrology (ASN) Kidney Week 2025, November 5-9 in Houston. "This ...

涉及的行业与公司 * 行业：中国医疗保健行业，特别是医学影像设备市场 [1][6][68] * 公司：上海联影医疗科技股份有限公司 [1][6][8] 核心观点与论据 财务业绩表现 * 公司第三季度收入为28.4亿元人民币，同比增长75.4% [8] * 前三季度各业务板块均实现增长：计算机断层扫描（CT）增长7.9%，磁共振（MR）增长40.2%，分子影像（MI）增长22.4%，X射线（XR）增长25.1%，放疗（RT）增长28.0%，服务收入增长28.4% [8] * 第三季度毛利率同比提升3.1个百分点，但环比下降1.6个百分点 [8] * 经常性净利润为8760万元人民币，利润率为3.1% [8] 中国市场表现与展望 * 公司在中国市场前三季度增长24%，远超整体影像市场约8%的同比增长，显示市场份额加速提升（MR份额+7个百分点，MI份额+18个百分点，RT份额+15个百分点）[2] * 2025年设备"以旧换新"计划实施速度快于2024年，可能持续至2026年上半年 [2] * 地方政府在第三季度响应"反内卷"运动，可能缓解行业内的非理性竞争 [2] * 对2026年中国影像市场增长持健康预期，基层医院可能获得类似或更大的"以旧换新"补贴支持 [2] 海外市场表现与展望 * 海外市场第三季度增长80%，占总收入约30%，管理层预计第四季度强劲势头将持续 [8] * 前三季度各地区表现：北美增长50%（约7亿元人民币，服务收入增长80%），欧洲增长超过100%（超过4亿元人民币），亚太地区（除中国外）增长20%以上，新兴市场（中东、拉丁美洲、非洲）增长30%（约2亿元人民币）[3] * 不断增长的设备装机量预计将支持经常性服务收入的增长和利润率扩张 [3] 产品发布与战略 * 计划于11月在中国、12月在海外RNSA上推出全套超声产品 [8] * 公司目标为2026年获得5亿元人民币订单并实现约3亿元人民币销售额 [8] * 公司未排除在香港交易所双重上市的可能性，但目前因现金充足尚无具体计划 [8] 费用与利润率展望 * 管理层目标2025年销售费用率、研发费用率和行政管理费用率分别约为16-17%、低于15%和约5% [4] * 预计2026年销售费用率和研发费用率将小幅下降 [4] 投资评级与估值 * 摩根士丹利给予公司"均配"评级，目标价158.00元人民币，较当前股价有约8%的上涨空间 [6] * 估值方法基于贴现现金流模型，关键假设包括加权平均资本成本8.8%，终端增长率4.0%，公司税率13.5% [9] 其他重要内容 潜在上行风险 * 有利的监管发展、市场份额增长、规模经济及审慎成本控制带来的利润率扩张、快速的海外扩张及经常性收入增长 [11] 潜在下行风险 * 意外的监管收紧、政府对资本开支的支持减少、市场份额流失、产品结构不利变化导致利润率恶化、海外扩张及经常性收入增长不及预期、地缘政治风险 [11] 公司基本信息 * 当前股价（2025年10月29日）为146.56元人民币，52周价格区间为115.00-164.50元人民币 [6] * 当前流通股本为8.24亿股，当前市值为1207.886亿元人民币 [6]

Smith & Nephew plc (NYSE:SNN) is included among the 11 Best FTSE Dividend Stocks to Buy Right Now. RBC Capital Raises Price Target on Smith & Nephew (SNN) Ahead of Capital Markets Day Smith & Nephew plc (NYSE:SNN), a g‍lobal m​e‍d‍ical technology company based in the UK, offers a wide range of products and services within the medical equipment i⁠ndustry to serve its customers’ needs. On Octob⁠er 20, RBC Capital rai⁠sed its pr⁠ice target‌ on Smith & Nephew plc (NYSE:SNN) to GB‌P1,700 from GBP 1,4‍00, whi ...